Condensed Consolidated Statements of Cash Flows Statement - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net Loss, Including Portion Attributable to Noncontrolling Interest	$ (9,897)	$ (13,552)
Adjustments to reconcile net loss including noncontrolling interests in operating subsidiaries to net cash used in operating activities:
Depreciation and amortization	10,803	13,101
Non-cash stock compensation	1,735	3,247
Other	69	(12)
Changes in assets and liabilities:
Restricted cash	(798)	(10,718)
Accounts receivable	8,325	(9,839)
Prepaid expenses and other assets	(134)	(702)
Accounts payable and accrued expenses	(2,733)	(2,133)
Royalties and contingent legal fees payable	3,740	4,778
Net cash used in operating activities	11,110	(15,830)
Cash flows from investing activities:
Maturities and sale of available-for-sale investments	0	18,579
Purchase of available-for-sale investments	0	(13,369)
Investments in patents/ patent rights	(1,000)	(16,861)
Purchases of property and equipment	(4)	0
Net cash provided by investing activities	(1,004)	(11,651)
Cash flows from financing activities:
Payments of Dividends	0	(6,375)
Proceeds from exercises of stock options	0	938
Net cash used in financing activities	0	(5,437)
Increase (decrease) in cash and cash equivalents	10,106	(32,918)
Cash and cash equivalents, beginning	135,223	134,466
Cash and cash equivalents, ending	145,329	101,548
Patent acquisition costs included in accrued patent acquisition costs	$ 0	$ 900